Consult with your health care provider before choosing a vaccine option. The CDC recommends a one-time RSV vaccine for ...

The other group at the highest risk when it comes to RSV is children under age five, and specifically infants—especially ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Just like adults under 60, elderly adults who get RSV tend to have mild symptoms, such as runny nose, sore throat, cough, ...

GSK has received approval for its vaccine, AREXVY, in Canada to prevent LRTD caused by RSV in adults aged 50 to 59 years.

Researchers found that vaccine effectiveness was 80% and 81% against RSV-associated hospitalizations and against RSV-associated critical illness among 28,271 hospitalizations for RSV-like illness ...

Health Canada has approved the vaccine, mRESVIA, for the prevention of lower respiratory tract disease in older adults, the company said.

The bivalent RSV prefusion F vaccine (Abrysvo) demonstrated 90% vaccine effectiveness (VE) in high-risk adults against ...

caused by respiratory syncytial virus (RSV) in adults aged 50 to 59 at increased risk for the disease. This expanded age indication approval stems from the positive outcomes of a Phase III ...

Oct. 30—(StatePoint) Each year, up to 160,000 older adults living in the United States are hospitalized and as many as 10,000 die due to respiratory syncytial virus (RSV).

Babies & Young Children RSV is so common, most kids have been infected with it by the age of 2. But that doesn’t mean it can’t be dangerous, especially for infants. In fact, according to the ...

Preliminary data were announced from 2 clinical trials evaluating Arexvy in a broader population of adults at increased for RSV disease.